NOT TO UNDERESTIMATE: THE POWER OF IMMUNOTHERAPY AND VDTP

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease or Lou Gehrig’s, is a neurodegenerative condition that results in the progressive loss of muscle control over voluntary movements. ALS poses one out of five chances for those who survive their first two decades on earth; however, this number can be reduced by 70% with early detection methods like routine check-ups alone!

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the progressive death of motor neurons leading to fatal paralysis. The exact causes of ALS are unknown; however, some studies believe the presence of autoimmune mechanisms contributing to pathogenesis. It cannot be denied that there is a role of autoimmunity in ALS.

There is a contribution of the innate immune system in ALS, with a role of microglial cell activation at the sites of neurodegeneration. Several therapeutic approaches have been proposed, including immunosuppressive drugs, to reduce disease progression. This post advances into understanding how immunotherapy or VDTP/GcMAF can be helpful in dealing with ALS and other autoimmune diseases.

VDTP/GcMAF and Autoimmune Diseases:

Gc protein-derived macrophage-activating factor (GcMAF) has various functions as an immune modulator, such as macrophage activation, anti-angiogenic activity and anti-tumor activity. Clinical trials of second-generation VDTP/GcMAF demonstrated remarkable clinical effects in several types of cancers. Thus, VDTP/GcMAF-based immunotherapy has a wide application for use in the treatment of many diseases including multiple sclerosis (MS), which is an autoimmune disorder affecting the myelinated axons in the central nervous system (CNS). Immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis (ALS).

Here’s a little more into what is VDTP/GcMAF!

Vitamin D Transport Protein (VDTP) is a multifunctional protein with a significant role. It carries vitamin D and its metabolites and acts as an actin scavenger and precursor of the macrophage activating factor molecule (VDTP/GcMAF). It has been reported to bear promising results against cancer, HIV, and neurological disorders, including autism, Alzheimer disease, chronic fatigue syndrome (CFS), among others (1). DBP leads to the formation of VDTP/GcMAF due to the loss of the O-glycosylated oligosaccharide moiety of the peptide by glycohydrolysis mediated by T and B cells (2).

Some studies suggest that an increase in levels of α-N-acetylgalactosaminidase (Nagalase) may lead to immunosuppression.

The vitamin D transport protein (VDTP) is the primary plasma carrier for vitamin D and its metabolites. Still, it is also an actin scavenger and is the precursor to the immunomodulatory protein, Gc-MAF. Two missense variants of the DBP gene, rs7041 and rs4588, change the amino acid sequence and alter the protein function.

DBP and vitamin D jointly or independently contribute to many adverse health outcomes unrelated to classical notions of their function in bone and mineral metabolism. Some studies (3) summarize the reports of associations between DBP variants and various chronic and infectious diseases.

What is GcMAF?

It is a human protein. One week’s VDTP/GcMAF looks like a small raindrop. It is perfectly sterile and the most ethical course for doctors. Taking VDTP/GcMaF replaces the immune system’s missing part and acts as the body’s internal medicine.

By extracting and isolating VDTP/GcMaF molecules, VDTP/GcMaF has undergone hundreds of laboratory experiments in universities, laboratories and clinics and has been the subject of 25 scientific research papers.

What does VDTP/GcMaF do?

VDTP/GcMaF is a far more powerful molecule than we thought, both in science and doctors’ results. In all stages of cancer, some doctors who choose the suitable complementary therapies are recovering a high percentage of patients, with high successes with many common cancers, including prostate (4), lung breast and melanoma, and leukaemia.

The immune system can eradicate chronic inflammation, bacterial and viral infections. VDTP/GcMaF has been successful with Autism, Chronic Herpes (5), Chronic Acne, Chronic cirrhosis of the liver, Chronic kidney disease, Chronic depression, Colitis, Crohn’s, Fibromyalgia, Hepatitis, LMBBS, ME/CFS, Osteoporosis, and various types of Immune dysfunction including allergies. Learn here how VDTP/GcMAF works in your body!

Research shows VDTP/GcMaF can halt deterioration in Parkinson’s, multiple sclerosis (6), dementia and ALS. VDTP/GcMAF has a significant role as an immune system regulator and can reverse diseases that attack the immune system like Lupus and Arthritis.

In addition to rebuilding an upset immune system, VDTP/GcMaF:

• Activates macrophages – phagocytosis and destruction of cancer cells.
• Reverts the cancer cell phenotype to normal (Turns cancer cells into healthy cells).
• Reduces the metastatic potential of human cancer cells in culture.
• Increases energy production at the mitochondrial level – ME/CFS
• Improves human neuronal metabolic activity through cAMP signalling – autism, ME/CFS, MS, ALS
• Counters toxic effects including cadmium – ME/CFS
• It abolishes neuropathic pain due to the lab’s neuro-oxidative stress (stress due to the anti-cancer drug oxaliplatin).
• It increases neuronal connectivity by promoting differentiation and the formation of dendrites and neuritis (autism and ME/CFS, where there is a lack of connectivity between neurons).
• Rebuilds a depressed immune system.

The function of VDTP/GCMAF

VDTP/GcMAF has 11 actions in a healthy person, including two on cells, three excellent effects on the brain, and six on cancer. It acts as a “director” of your immune system. But viruses and malignant cells like cancer send out an enzyme called Nagalase that prevents the production of VDTP/GcMAF. This neutralises the immune system, allowing diseases to become chronic and cancer cells to grow unchecked.

Minutes after receiving immunotherapy, ten of the actions restart. In three months, the immune system is believed to be rebuilt to above normal strength depending on the severity of disease and function. Two or three doses a week, typically for 12 weeks for chronic diseases and early cancers, is advised by researchers. The condition is known to be taken down without side effects and successfully in up to 80% of cases -depending upon how well you follow the treatment protocol, supplements and diet!

Conclusion:

The available data from studies explain that DBP variants are a significant and common genetic factor in most common disorders. This needs closer attention, especially given the heightened interest in vitamin D as a public health target. Well-designed studies that look simultaneously at vitamin D and its carrier in relation to genotypes and adverse health outcomes should be encouraged.

Many proven reasons have forced cancer patients to turn to immunotherapy for cancer.

We see so much lack of care sometimes when all that is needed is a change in diet, healthier lifestyle, getting natural Vitamin D and some exercise, and there would be fewer problems across the western world. God gave us a body, a vessel to sail in; the least you can do is look after it while you are using it.

If you are having problems sourcing a genuine product, please contact: [email protected] for more enquiries on VDPT/GcMaf

References and Sources:

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686300/
2. https://pubmed.ncbi.nlm.nih.gov/24101054/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613945/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2510818/
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7124316/
6. https://pubmed.ncbi.nlm.nih.gov/27354653/#:~:text=Results%3A%20This%20case%20study%20demonstrated,in%20the%20treatment%20of%20MS.